Market watch: Landscape for medical countermeasure development
Nature Reviews Drug Discovery 16, 448 (2017).
doi:10.1038/nrd.2017.80
Authors: Christopher Milne, Zachary Peter Smith & Ranjana Chakravarthy
Medical countermeasures (MCMs) encompass biologics, drugs or devices that may be used for biodefence against biological, chemical or radiological bioweapons, or in the event of naturally occurring emerging and re-emerging diseases, or natural disasters. Since 2008, the Tufts Center for the Study of Drug Development (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 5, 2017 Category: Drugs & Pharmacology Authors: Christopher Milne Zachary Peter Smith Ranjana Chakravarthy Tags: News and Analysis Source Type: research
Bridging the translational innovation gap through good biomarker practice
Nature Reviews Drug Discovery 16, 587 (2017).
doi:10.1038/nrd.2017.72
Authors: Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders & Anton Ussi
Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — ar...
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Alain J. van Gool Florence Bietrix Eric Caldenhoven Kurt Zatloukal Andreas Scherer Jan-Eric Litton Gerrit Meijer Niklas Blomberg Andy Smith Barend Mons Jaap Heringa Wim-Jan Koot Martin J. Smit Marian Hajduch Ton Rijnders Anton Ussi Tags: Comment Source Type: research
Implications of cancer evolution for drug development
Nature Reviews Drug Discovery 16, 441 (2017).
doi:10.1038/nrd.2017.78
Authors: Samra Turajlic & Charles Swanton
Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Samra Turajlic Charles Swanton Tags: Comment Source Type: research
Aptamers as targeted therapeutics: current potential and challenges
Nature Reviews Drug Discovery 16, 440 (2017).
doi:10.1038/nrd.2017.86
Author: Jiehua Zhou & John Rossi
Nature Reviews Drug Discovery16, 181–202 (2017)Base Pair Biotechnologies and Apterna were omitted from Table 3 in this article. These have now been included. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Jiehua Zhou John Rossi Tags: Corrigendum Source Type: research
Advances in islet encapsulation technologies
Nature Reviews Drug Discovery 16, 367 (2017).
doi:10.1038/nrd.2017.67
Author: Tejal Desai & Lonnie D. Shea
Nature Reviews Drug Discovery, doi:10.1038/nrd.2016.232In this article, the University of Edmonton was referred to instead of the University of Alberta and the article cited as reference 10 was incorrect. These errors have been corrected in the online version. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Tejal Desai Lonnie D. Shea Tags: Correction Source Type: research
Regenerative medicine: Targeting adaptor protein interactions for nerve regrowth
Nature Reviews Drug Discovery 16, 314 (2017).
doi:10.1038/nrd.2017.85
Author: Katie Kingwell
CNS neurons show limited capacity for spontaneous repair after injury, which hampers functional recovery in conditions such as stroke and traumatic brain injury. Now, a study in Neuron has shown that a small molecule, fusicoccin A (FC-A), promotes axon growth after injury in mice (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: Research Highlight Source Type: research
Anticancer therapy: Re-educating macrophages
Nature Reviews Drug Discovery 16, 313 (2017).
doi:10.1038/nrd.2017.82
Author: M. Teresa Villanueva
Despite being the main effectors of the innate immune response and programmed to detect and eliminate mutated cells, macrophages can change their phenotype and become pro-tumorigenic in response to cues from the tumour. Given their position within the tumour mass, tumour-associated macrophages (TAMs) are an (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: M. Teresa Villanueva Tags: Research Highlight Source Type: research
Thomas Lynch
Nature Reviews Drug Discovery 16, 308 (2017).
doi:10.1038/nrd.2017.69
Bristol-Myers Squibb has one of the deepest immuno-oncology drug pipelines, with checkpoint inhibitors, T cell and natural killer cell agonists, and metabolic modulators of the tumour microenvironment. Despite a setback with its marketed checkpoint inhibitor nivolumab in a first-line lung cancer setting last year, there are still high hopes for these emerging therapies. In March, the company hired Thomas Lynch — former CEO of Massachusetts General Physicians Organization and Director of the Yale Cancer Center — as its new Chief Scient...
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
FDA approves dupilumab for severe eczema
Nature Reviews Drug Discovery 16, 305 (2017).
doi:10.1038/nrd.2017.90
Author: Asher Mullard
The FDA approved Regeneron and Sanofi's first-in-class candidate dupilumab for the treatment of moderate-to-severe eczema.T helper 2 type responses have emerged as a unifying feature of various inflammatory and allergic diseases, such as eczema and asthma. As a result, type 2 cytokines — (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
FDA approves first deuterated drug
Nature Reviews Drug Discovery 16, 305 (2017).
doi:10.1038/nrd.2017.89
Author: Asher Mullard
The FDA approved Teva Pharmaceuticals' deutetrabenazine for chorea associated with Huntington disease, providing the first approval of a drug that contains the heavy hydrogen isotope deuterium.Early adopters first started tinkering with the use of deuterium in drug candidates more than 50 years ago. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
FDA approves first drug for primary progressive multiple sclerosis
Nature Reviews Drug Discovery 16, 305 (2017).
doi:10.1038/nrd.2017.88
Author: Asher Mullard
The FDA approved Roche's ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis (PPMS), wrapping up a 40-year development history for the anti-CD20 monoclonal antibody (mAb). This is the first drug approval for PPMS, a form of the neurodegenerative disease that (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
CAR T therapies drive into new terrain
Nature Reviews Drug Discovery 16, 301 (2017).
doi:10.1038/nrd.2017.84
Author: Katie Kingwell
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: News and Analysis Source Type: research
Nine paths to PCSK9 inhibition
Nature Reviews Drug Discovery 16, 299 (2017).
doi:10.1038/nrd.2017.83
Author: Asher Mullard
A lipid-modulating protein that exemplifies the value of human genetics for target validation has provided a fertile testing ground for new drug modalities including long-acting RNA interference drugs, vaccines against self-antigens, CRISPR therapeutics and small molecules that control ribosomal activity. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
Advances in islet encapsulation technologies
Nature Reviews Drug Discovery 16, 367 (2017).
doi:10.1038/nrd.2017.67
Author: Tejal Desai & Lonnie D. Shea
Nature Reviews Drug Discovery, doi:10.1038/nrd.2016.232In this article, the University of Edmonton was referred to instead of the University of Alberta and the article cited as reference 10 was incorrect. These errors have been corrected in the online version. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Tejal Desai Lonnie D. Shea Tags: Correction Source Type: research
Regenerative medicine: Targeting adaptor protein interactions for nerve regrowth
Nature Reviews Drug Discovery 16, 314 (2017).
doi:10.1038/nrd.2017.85
Author: Katie Kingwell
CNS neurons show limited capacity for spontaneous repair after injury, which hampers functional recovery in conditions such as stroke and traumatic brain injury. Now, a study in Neuron has shown that a small molecule, fusicoccin A (FC-A), promotes axon growth after injury in mice (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - April 28, 2017 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: Research Highlight Source Type: research
